Keppra Tablet, Film Coated, Extended Release
Product Images NDC 50474-598

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Keppra (NDC 50474-598). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ucb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Keppraxr 01)

Chemical structure diagram of levetiracetam, the active ingredient in Keppra XR. The structure shows a pyrrolidone ring with attached ethyl, carbonyl, and amide functional groups, consistent with levetiracetam's molecular configuration.*

FDA Label Image

Figure 1 (Keppraxr 02)

A vertical bar chart comparing the percentage of patients among three groups: Placebo (7.4%), Immediate-release Keppra 1000 mg/day (37.1%), and Immediate-release Keppra 3000 mg/day (39.6%). The y-axis represents the percentage of patients, and each bar is labeled with the exact percentage value and sample size (N).*

FDA Label Image

Figure 2 (Keppraxr 03)

A bar chart depicting the percentage of patients experiencing an unspecified outcome across three groups: Placebo (6.3%, N=111), Immediate-release Keppra 1000 mg/day (20.8%, N=106), and Immediate-release Keppra 2000 mg/day (35.2%, N=105). The y-axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Figure 3 (Keppraxr 04)

A bar graph showing the percentage of patients responding in two groups: Placebo and Immediate-release Keppra at 3000 mg/day. The placebo group (N=104) shows 14.4% of patients, and the Immediate-release Keppra group (N=180) shows 39.4% of patients. The y-axis is labeled '% of Patients', ranging from 0% to 45%.*

FDA Label Image

Figure 4 (Keppraxr 05)

A bar chart comparing the percentage of patients between two groups: Placebo (N=97) and Immediate-release Keppra (N=101). The y-axis represents the percentage of patients, showing 19.6% for Placebo and 44.6% for Immediate-release Keppra.*

FDA Label Image

Principal Display Panel (500 mg Tablet Bottle Label)

Keppra XR 500 mg extended-release tablets label, showing the brand and generic name levetiracetam. The label indicates a 60-tablet quantity with once daily dosing. It includes dispensing instructions, storage conditions, and the manufacturer UCB, Inc., Smyrna, GA. The label also displays a barcode and RX only designation.*

FDA Label Image

Principal Display Panel (750 mg Tablet Bottle Label)

Keppra XR 750 mg extended-release tablets packaging label by UCB, Inc. The label displays the product name with levetiracetam as the active ingredient. It contains 60 tablets for once daily dosing. Storage and dispensing instructions, barcode, lot, and expiration information spaces are included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.